[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB0402129D0 - Therapeutic and diagnostic peptides - Google Patents

Therapeutic and diagnostic peptides

Info

Publication number
GB0402129D0
GB0402129D0 GBGB0402129.1A GB0402129A GB0402129D0 GB 0402129 D0 GB0402129 D0 GB 0402129D0 GB 0402129 A GB0402129 A GB 0402129A GB 0402129 D0 GB0402129 D0 GB 0402129D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic
diagnostic peptides
peptides
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0402129.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB0402129.1A priority Critical patent/GB0402129D0/en
Priority to US10/783,095 priority patent/US7049292B2/en
Priority to CA2456593A priority patent/CA2456593C/en
Publication of GB0402129D0 publication Critical patent/GB0402129D0/en
Priority to PCT/GB2005/000236 priority patent/WO2005073248A1/en
Priority to EP05701998.6A priority patent/EP1709070B1/en
Priority to AU2005209464A priority patent/AU2005209464B2/en
Priority to ES05701998T priority patent/ES2432441T3/en
Priority to PL05701998T priority patent/PL1709070T3/en
Priority to US11/370,168 priority patent/US20060199228A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB0402129.1A 2004-01-30 2004-01-30 Therapeutic and diagnostic peptides Ceased GB0402129D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0402129.1A GB0402129D0 (en) 2004-01-30 2004-01-30 Therapeutic and diagnostic peptides
US10/783,095 US7049292B2 (en) 2004-01-30 2004-02-23 Therapeutically effective peptides related to preproinsulin
CA2456593A CA2456593C (en) 2004-01-30 2004-02-27 Peptides for the diagnosis, monitoring and treatment of diabetes
PCT/GB2005/000236 WO2005073248A1 (en) 2004-01-30 2005-01-24 Peptides for treatment of autoimmune diseases
EP05701998.6A EP1709070B1 (en) 2004-01-30 2005-01-24 Peptides for treatment of autoimmune diseases
AU2005209464A AU2005209464B2 (en) 2004-01-30 2005-01-24 Peptides for treatment of autoimmune diseases
ES05701998T ES2432441T3 (en) 2004-01-30 2005-01-24 Peptides for the treatment of autoimmune diseases
PL05701998T PL1709070T3 (en) 2004-01-30 2005-01-24 Peptides for treatment of autoimmune diseases
US11/370,168 US20060199228A1 (en) 2004-01-30 2006-03-08 Peptides for treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402129.1A GB0402129D0 (en) 2004-01-30 2004-01-30 Therapeutic and diagnostic peptides

Publications (1)

Publication Number Publication Date
GB0402129D0 true GB0402129D0 (en) 2004-03-03

Family

ID=31971793

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0402129.1A Ceased GB0402129D0 (en) 2004-01-30 2004-01-30 Therapeutic and diagnostic peptides

Country Status (3)

Country Link
US (1) US7049292B2 (en)
CA (1) CA2456593C (en)
GB (1) GB0402129D0 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129307A1 (en) * 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
US10473647B1 (en) 2014-11-21 2019-11-12 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
GB201510056D0 (en) 2015-06-10 2015-07-22 King S College London Multi-peptide composition
WO2017125586A2 (en) * 2016-01-22 2017-07-27 Academisch Ziekenhuis Leiden (Also Acting Under The Name Of Leiden University Medical) Insulin gene-derived proteins and peptides for use in the diagnosis and treatment of type 1 diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034882A1 (en) * 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
ATE328605T1 (en) * 2000-03-24 2006-06-15 Genentech Inc USE OF INSULIN TO TREAT CARTILAGE DISEASES

Also Published As

Publication number Publication date
CA2456593A1 (en) 2005-07-30
CA2456593C (en) 2014-01-28
US20050176637A1 (en) 2005-08-11
US7049292B2 (en) 2006-05-23

Similar Documents

Publication Publication Date Title
IL261346A (en) Tissue protective peptides and uses thereof
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
EP1874800A4 (en) Diagnostic and therapeutic agents
EP1751179A4 (en) Casein derived peptides and therapeutic uses thereof
EP1951280A4 (en) Peptides for diagnostic and therapeutic methods for celiac sprue
GB0722996D0 (en) Depsipeptides and their therapeutic use
EP1758605A4 (en) Prouroguanylin as therapeutic and diagnostic agents
EP1893233A4 (en) Therapeutic peptides and vaccines
EP1825005A4 (en) Mer diagnostic and therapeutic agents
EP2097093A4 (en) Therapeutic and diagnostic peptides
EP1781685A4 (en) Therapeutic and diagnostic agents
EP1838288A4 (en) Therapeutic materials and methods
IL178517A0 (en) Therapeutic peptides
GB0407382D0 (en) Therapeutic methods and means
GB0402129D0 (en) Therapeutic and diagnostic peptides
SG122903A1 (en) Therapeutic peptides and method
EP1951914A4 (en) Diagnostic and therapeutic methods and agents
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0526120D0 (en) Therapeutic peptides
ZA200800566B (en) Therapeutic peptides and vaccines
ZA200802541B (en) Human antibodies against IL13 and therapeutic uses
GB0512726D0 (en) Multiple sclerosis therapy and diagnosis
ZA200609395B (en) Therapeutic peptides
GB0404199D0 (en) Therapeutic and diagnostic peptides 2
GB0419594D0 (en) Therapeutic peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)